//@洛鸿:你看不懂那就等开盘吧，这个数据是目前新冠危重症领域最好的数据了//@karaloo:March 31, 2022 - 7:30 amVilobelimab treatment results in relative reduction in 28-day all-cause mortality of 23.9% compared to placebo (p-value=0.094), but did not show statistical significance on the pre-specified primary endpointPre-specified sensitivity analysis of the primary endpoint results in p-values of <0.05 in three out of four planned analyses in favor of vilobelimab treatment43% relative reduction in 28-day all-cause mortality detected in pre-specified subgroup analysis in Western European patients comparing vilobelimab to placebo treatment (n=209, p-value=0.014)Additional pre-specified subgroup analyses in patients with more severe disease confirm treatment benefit for vilobelimab, resulting in p-values of <0.05Company plans to discuss results with regulatory authoritiesCompany to host a conference call today at 8:30 am EDT/2:30 pm CEST